Federal Circuit Rules For Shwarz Pharma In Suit Over Univasc Patent

Law360, New York (February 1, 2004, 12:00 AM EST) -- The U.S. Court of Appeals for the Federal Circuit has vacated a lower court’s decision that supported Israeli generics maker Teva's right to sell a generic form of Schwarz Pharma’s hypertension drug Univasc.

The U.S. District Court for the District of New Jersey had found that Teva's product, Moexipril HCl Tablets,would not infringe U.S. Patent No. 4,743,450, asserted by Schwarz Pharma as licensee of Warner Lambert. However, the Court of Appeals has remanded the case to the District Court for further proceedings, Teva said.

“Yesterday's ruling...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.